A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

NCT06185543 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Company will improve study desig

Conditions

Alzheimer Disease

Interventions

DRUG: PrimeC
DRUG: Placebo

Sponsor

NeuroSense Therapeutics Ltd.